Research News

Cancer drug shows promise for multiple sclerosis

BMJ 2012; 345 doi: (Published 05 November 2012) Cite this as: BMJ 2012;345:e7469

Two manufacturer sponsored phase III trials suggest that alemtuzumab, an anti-CD52 monoclonal antibody that is licensed to treat leukaemia, may help control multiple sclerosis. Both trials lasted two years and compared alemtuzumab with interferon beta-1a, which is considered first line treatment. One trial looked at 563 patients who had not yet undergone treatment for multiple sclerosis, whereas the other trial looked at …

View Full Text

Log in

Log in through your institution


* For online subscription